News >

Ruxolitinib/Etanercept Combo Resolves Steroid-Refractory Acute GVHD Following Allogeneic SCT

Virginia Powers, PhD
Published: Monday, Apr 01, 2019

A novel treatment of ruxolitinib (Jakafi) combined with etanercept (Enbrel) led to encouraging response and survival rates in patients who developed grades 3/4 steroid-resistant acute graft-versus-host disease (GVHD) after undergoing allogeneic stem cell transplantation (SCT), according to findings presented at the 2019 European Society for Blood and Marrow Transplantation Annual Meeting.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 3rd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesNov 29, 20192.0
Advances in™ ALL: The Role of T-Cell Engaging Immunotherapy in Treating Relapsed DiseaseNov 30, 20191.0
Publication Bottom Border
Border Publication